RoadMap (Plaque Analysis System)

2022: Announcement System

In mid-October 2022, HeartFlow launched a plaque analysis system to assess heart attack risks based on artificial intelligence.

HeartFlow has developed its technology based on coronary computed tomographic angiography (CCTA). She now offers non-invasive information on anatomy, physiology and plaque in coronary arteries, based on computed tomographic angiography (CTA) data.

Plaque analysis system released to assess heart attack risks

The company said in a press release that it is the first to offer all three types of information based on KTA. RoadMap provides coronary artery anatomy. HeartFlow's FFRCT offers physiology, and Plaque analysis provides plaque information. Overall, these products allow physicians to gain a more complete understanding of coronary artery disease (CAD). According to the developers of the technology, the system allows you to accurately predict the risk of a heart attack.

{{quote 'Permission 510 (k) to use our Plaque and RoadMap assays represents an important milestone in the company's commitment to providing physicians with richer clinical information to diagnose and treat individual patients, regardless of their position on the coronary spectrum! The plaque and RoadMap analyses, together with HeartFlow's FFRCT, create the HeartFlow technology platform and allow continued development of AI-based risk scoring to better identify asymptomatic patients at risk of heart attack, said HeartFlow President and CEO John Farquhar. }} RoadMap allows computed tomography specialists to improve CAD diagnostics. It provides imaging and quantification of the location and severity of anatomical narrowings in the coronary arteries on each KTA. HeartFlow plans to begin real-world clinical use of the Plaque and RoadMap analysis in some U.S. hospitals and health care systems after obtaining approval from the U.S. Department of Health.^[1]

Notes